Objectives: To determine whether carbamazepine (CBZ) aggravates absence seizures in the low-dose pentylenetetrazol (PTZ) rat model in both male and female animals, and investigate for gender differences. Methods: Inbred Sprague-Dawley rats were implanted with EEG electrodes. Seven days later PTZ (20 mg/kg, i.p.) was administered following pre-treatment with vehicle or CBZ (20 mg/kg, i.p.) and the occurrence of spike-and-wave discharges (SWDs) on the EEG quantified. Results: The cumulative SWD for 90-minute post-PTZ was higher in the CBZ versus vehicle pre-treatment arm for both female (mean 110 seconds vs. 62 seconds; P = 0.03) and male (mean 89 seconds vs. 60 seconds; P = 0.03) rats. The increase in SWD duration in the CBZ arm was greater in female rats for the first five 15-minute intervals, but none attained statistical significance (P > 0.05). CBZ pre-treatment resulted in reductions in both SWD frequency (Hz) (male, P = 0.003; female, P < 0.0001) and latency to onset of SWD (male, P = 0.002). The frequency of SWD in CBZ pre-treated rats was lower in females (5.8 Hz vs. 6.1 Hz, P = 0.02) as was the decrease in the SWD burst duration following CBZ versus vehicle pre-treatment (−0.05 seconds vs. −0.25 seconds, P = 0.046). Conclusions: CBZ consistently aggravates absence seizures in the low-dose PTZ model in both female and male rats. However, while some gender differences were found, the results failed to support the hypothesis that females are significantly more susceptible to aggravation of the number or duration of absence seizures by CBZ.
INTRODUCTION
The introduction of effective and well tolerated antiepileptic drugs (AEDs) has allowed successful seizure control to be achieved in the majority of patients with epilepsy. However, it is now increasingly being recognised that AEDs can, in some circumstances, paradoxically aggravate the frequency and severity of seizures [1] [2] [3] [4] . The mechanisms by which AEDs aggravate seizures have remained largely unexplored, but have many important implications. These include a better understanding of the underlying pathophysiology of seizures, guiding more targeted and rational drug design, and in allowing an improved clinical selection of AEDs for individual patients that minimises the likelihood of this occurrence.
An important example of the aggravation of seizures by an AED is observed with carbamazepine (CBZ). This drug is generally considered the drug of choice for patients with focal epilepsy syndromes 5, 6 . However, in patients with generalised epilepsies, CBZ often results in an increase in the frequency and severity of typical and atypical absence seizures 4 .
On occasions the aggravation of absence seizures by CBZ can be so prominent as to clinically and electrographically resemble complex partial seizures 3 . Furthermore, CBZ has been reported to provoke absence (non-convulsive) status epilepticus that is resistant to treatment 7 . Absence seizures may also be provoked 'de novo' by CBZ in patients without a previous history of this seizure type 7 . In agreement with human studies, CBZ has also been reported to exacerbate animal absence seizure models including the genetic absence epilepsy-prone rats from Strasbourg (GAERS) 8 , the low-dose pentylenetetrazol (PTZ) model in rats 9 , and in the AY rat model of atypical absence epilepsy 10 .
There is clinical evidence that there may be a sex difference in the susceptibility of post-pubescent patients to the aggravation of absence seizure by CBZ, with the vast majority of such reported cases being pre-menopausal women 7, [11] [12] [13] [14] [15] [16] . Furthermore, absence seizures persisting into adulthood are more common in females, and the frequency of absence epilepsy in adults is positively correlated with progesterone levels 17 . However, previous animal studies of CBZ aggravation of absence seizures have been conducted on male animals and have not investigated a possible gender effect. Therefore, the aims of the experiments in this paper were to determine whether CBZ aggravated absence seizures in the low-dose PTZ rat model in female as well as male animals, and whether this was influenced by the gender of the animal.
METHODS

Low-dose PTZ rat model of absence seizures
The low-dose PTZ model has been well validated and fulfils accepted criteria for an animal model of human absence epilepsy 18 . Intraperitoneal (i.p.) doses of 20 mg/kg PTZ have been shown to reliably result in seizures with EEG and behavioural changes that are similar to those seen in human absence seizures, with bilaterally synchronous spike-and-wave discharges (SWDs) on the EEG accompanied by behavioural arrest with vibrissal and facial twitching [19] [20] [21] [22] [23] [24] [25] . In contrast, higher PTZ doses (40-60 mg/kg) induce seizures with clonic motor activity associated with fast trains of spike discharges on the EEG 21 . Absence seizures induced by low-dose PTZ have been shown to peak at approximately 20 minutes following i.p. injection, and cease within 80-100 minutes 20 .
Animals
Eleven male (370-428 g) and 12 female (207-249 g) inbred Sprague-Dawley rats between the age of 11-14 weeks old were studied. Rats were housed together (up to four per cage) prior to surgical intervention and individually following surgery, and maintained at 22 • C on a 12-hour light:12-hour dark cycle (lights on 07:00 hour) with food and water available ad libitum. All experiments were performed in accordance with the Prevention of Cruelty to Animals Act 1986, Victoria, under the guidelines of the National Health and Medical Research Council of Australia Code of Practice. The study protocol was approved by the St. Vincent's Hospital Animal Ethics Committee.
Surgery
The analgesic Rimadyl (5 mg/kg; s.c.) was administered pre-operatively to all rats. Under general (pentobarbitone 45-60 mg/kg, i.p. initially and supplemented during the procedure if required) and local (lignocaine 15 mg/kg, s.c.) anaesthesia, a single midline incision was made to expose the skull. Burr holes were drilled at each electrode site and five nickel alloy jeweller screws (1.4 mm × 3.5 mm) were inserted into the skull over the frontal and parietal areas bilaterally (2.5 mm lateral to mid-line-two screws anterior and three screws posterior to bregma). Prior to electrode implantation, a 1.5-mm diameter gold 'male' connector had been soldered to the head of each screw to enable the attachment of EEG electrodes/leads to the EEG pre-amplifier system during the recordings. Dental cement was used to fix the electrodes in place. All rats were allowed at least 7 days recovery prior to the commencement of the experimental procedures outlined below.
Experimental design and EEG recordings
The experiments were performed with the rats in a large, open plastic box. Electrodes were attached to leads which were then connected to a commercial portable digital EEG machine to allow continuous recording of the EEG in freely moving rats. All rats had a 15-minute habituation period immediately prior to the recording period followed by a 15-minute baseline recording. Rats were then administered either vehicle (70% propylene glycol, 28% ethanol and 2% Tween 20) or CBZ (20 mg/kg, i.p.) and then 15 minutes later a low-dose of PTZ (20 mg/kg, i.p.). Subsequent to the PTZ injection, the EEG was recorded continuously for a further 90 minutes. At least one recovery/drug-free day was given between the two injection days to minimise the possibility of residual influences from the drugs administered on the first injection day. The injections of vehicle and CBZ were also randomised to eliminate any possible 'order' effect. Following the completion of the experimental protocol described the rats were subjected to chemical euthanasia using pentobarbitone (100 mg/kg, i.p.).
Vaginal smears
The stage of the rats' oestrous cycle was determined at the time of surgery and at the completion of each recording session. Smears were obtained by placing a blunted glass rod containing a drop of distilled water into the vaginal opening. Cells were smeared onto a glass microscope slide, allowed to air-dry and then fixed with 100% methanol. Slides were then placed in Giemsa stain for approximately 30 minutes, rinsed in water and examined under a microscope. Phases of the oestrous cycle were characterised according to the following criteria: (1) Proestrous-large round nucleated epithelial cells; (2) Oestrous-dense masses of cornified squamous epithelial cells; (3) Metestrous-leukocyte infiltration with nucleated epithelial cells present; and (4) Diestrous-predominance of leukocytes 26 . Drugs PTZ, CBZ, Giemsa stain, Tween 20, propylene glycol were all purchased from Sigma-Aldrich, Australia. The following agents are listed with their respective suppliers: rimadyl (Pfizer, Australia), pentobarbitone (Rhône Mérieux, Australia), lignocaine (Delta West, Australia) and self-curing dental cement (Halas Dental Supplies, Australia). PTZ was dissolved in sterile saline for injection. CBZ was dissolved in a mixture of propylene glycol, ethanol and Tween 20 (see above) and mild heating and stirring aided the dissolution of the compound into solution. All drug injections were administered at a volume of 2 ml/kg.
Data analysis
Absence seizures induced by the administration of low-dose PTZ were quantified by measuring the (a) duration (second) of SWD for each of six sequential 15-minute interval post-PTZ administration, (b) total cumulative duration (seconds) of SWD over the post-PTZ 90-minute recording, (c) mean SWD frequency (Hz)-calculated by the number of spikes per second, (d) individual SWD burst duration (seconds), (e) absolute number of SWD bursts over the 90-minute recording, and (f) latency to onset of first SWD (minutes). A strict criteria was used for defining the SWD bursts and their duration, with only the section of the discharge where there was clear rhythmic spike and wave activity (frequency 4-8 Hz) being counted (Fig. 1) . The Student's paired t-test was used to compare the above variables between the CBZ and the vehicle experimental arms in both male and female rats. A Student's unpaired t-test was used to compare between male and female rats for the above variables for both the CBZ and vehicle arms. Similarly, the difference in these variables between the CBZ pre-treatment and the vehicle pre-treatment arms (i.e. CBZ−vehicle) was compared between male and female rats using a Student's unpaired t-test. The level for determining statistical significance was set at P < 0.05 for all tests.
RESULTS
SWD duration
Systemic administration of low-dose PTZ resulted in bursts of bilaterally synchronous SWD in all male and female rats examined, which were associated with periods of immobility and staring (Fig. 1 ). Fig. 2 shows the cumulative duration of SWD during each 15-minute interval following systemic administration of PTZ in vehicle-and CBZ-pre-treated male ( Fig. 2A) and female (Fig. 2B) rats. In female rats, the cumulative duration of SWD was significantly greater following CBZ pre-treatment compared following vehicle pre-treatment for the 0-15 minute (P = 0.002), 15-30 minute (P = 0.018) and 30-45 minute (P = 0.02) post-PTZ time intervals, but not for the 45-60, 60-75 or 75-90 minute intervals (all P > 0.05, paired t-test). In male rats, CBZ pre-treatment significantly increased the cumulative SWD duration for the 0-15 minute (P = 0.02) and the 30-45 minute (P = 0.004) post-PTZ time intervals, but not at the 15-30, 45-60, 60-75 or 75-90 minute intervals (all P > 0.05, paired t-test). Fig. 3 compares male and female rats with regard to the magnitude of the increase in the SWD duration following CBZ (vs. vehicle) pre-treatment for the six post-PTZ time intervals. This increase was greater in female rats for all but the last time interval, however, none individually attained statistical significance (all P > 0.05, unpaired t-test).
The cumulative duration of SWDs for the total 90-minute post-PTZ recording was significantly greater in the CBZ pre-treatment arm (compared to the vehicle arm) in both female and male rats (P = 0.03 for both, paired t-test) ( Table 1 ). The total cumulative SWD duration did not significantly differ between male and female rats in either the vehicle-or CBZ-pre-treated groups (Table 1) . Additionally, while the increase in cumulative SWD duration between the CBZ pre-treatment and the vehicle pre-treatment arm was somewhat higher in female (48 seconds) versus male (29 seconds) rats, this difference did not attain statistical significance (P > 0.05, unpaired t-test).
SWD frequency
The PTZ-induced SWD frequency results are summarised in Table 1 . Pre-treatment with CBZ resulted in a significant reduction in SWD frequency in both female (P < 0.0001) and male rats (P = 0.003, paired t-test). Moreover, following CBZ pre-treatment the SWD frequency was significantly lower in female compared with male rats (P = 0.
02, unpaired t-test).
There was no significant sex difference observed in SWD frequency in vehicle pre-treated rats (P = 0.06). Female and male animals did not significantly differ in the mean difference in SWD frequency between the CBZ and vehicle arms (−0.57 Hz vs. −0.45 Hz, P > 0.05, unpaired t-test).
SWD burst duration
The results for the burst duration of SWD are summarised in Table 1 . Pre-treatment with CBZ reduced the SWD burst length when compared with vehicle pre-treatment, however, this only attained a level of significance in the male rats (P = 0.02, paired t-test).
There was no significant difference in the burst duration of SWD between female and male rats for either the vehicle or CBZ pre-treated groups (P > 0.05, unpaired t-tests). Female rats had a significantly smaller decrease in the mean SWD burst length between the CBZ and vehicle arms compared with male rats (−0.05 seconds vs. −0.25 seconds, P < 0.05, unpaired t-test).
Numbers of SWD bursts
The results for the absolute number of SWDs occurring over the 90-minute post-PTZ recording are summarised in Table 1 . The number of bursts were significantly greater following CBZ pre-treatment for both female (P = 0.017, paired t-test) and male (P = 0.005, paired t-test) rats. There were no significant differences between genders in the mean number of SWD bursts for either the CBZ or vehicle pre-treatment arms (all P > 0.05, unpaired t-tests). Female and male rats did not significantly differ in the mean difference in number of SWD bursts between the CBZ and vehicle arms (51 vs. 40, P > 0.05, unpaired t-test).
Latency to SWD onset
The results for the latency to onset of SWD following administration of PTZ are summarised in Table 1 . In both female and male rats, CBZ pre-treatment reduced the time to SWD onset, however, this only attained a level of significance in male rats (P = 0.002, paired t-test). No significant sex difference was observed in the latency to SWD onset in either the vehicle or the CBZ-treated group (P > 0.05, unpaired t-test). Female and male rats did not significantly differ in the mean difference in the latency to SWD onset between 
unpaired t-test).
Stage of the oestrous cycle
There was no obvious relationship between the stage of the oestrous cycle and the degree of absence seizure aggravation by CBZ in the female rats examined (Table 2) .
DISCUSSION
This study demonstrated that CBZ (20 mg/kg, i.p.) consistently aggravates the cumulative duration, absolute number, and the latency to onset of experimental absence seizures in the low-dose PTZ rat model, for both female and male animals ( Table 1) . This is consistent with the clinical observations of the aggravation of seizures by CBZ in patients with absence epilepsy 3, 4, 7 . A previous study in male Wistar rats had found that the pre-administration of CBZ (10 and 20 mg/kg, i.p.) increased SWD in both rats that exhibited spontaneous absence seizures and in non-epileptic rats administered low-dose PTZ 9 . Similarly, another study demonstrated that CBZ (doses 20-80 mg/kg, i.p.) aggravated the duration of spontaneous SWDs in (presumably male) GAERS 8 . In a more recent study the pre-administration of CBZ (10 mg/kg, i.p.) to non-epileptic male Wistar rats was shown to worsen absence seizures induced by low-dose PTZ 22 . Our current study extends previous findings by also demonstrating aggravation of experimental absence seizures in female rats. Moreover, this is the first report to explore the effects of gender on CBZ-induced absence seizure exacerbation. The mechanism(s) underlying the exacerbation of absence seizures by CBZ are currently uncertain and remain largely unexplored. Although CBZ is believed to primarily exert its antiepileptic action via a use-dependent inhibition of voltage-gated sodium channels 27 , it has other modes of action, not all of which are currently well defined, and many of which are likely to be specific to certain cerebral sites or cell types 28 . The primary underlying neurophysiological correlate of absence seizures is bursts of highly synchronised rhythmic oscillatory glutamatergic firing between neurons in the thalamic relay nuclei and neocortical pyramidal neurons 29 . This activity is synchronised by the nucleus reticularis thalami (NRT) which is principally composed of GABAergic neurons that project to almost all thalamic relay nuclei 18 . The NRT neurons in turn receive excitatory glutamatergic inputs from axon collateral fibres from the thalamocortical and corticothalamic neurons. The NRT neurons regulate the oscillatory thalamocortical activity via GABA B -receptor mediated inhibitory postsynaptic potentials (IPSP) which induce hyperpolarisation of thalamic relay neurons triggering a low threshold calcium spike, which in turn give rise to a rebound burst of high frequency action potentials 29 .
GABAergic mechanisms play a pivotal role in the generation and regulation of absence seizures. Drugs that enhance GABA function in the brain, such as vigabatrin and tiagabine, exacerbate both experimental and clinical absence seizures 29, 30 . Activation of both GABA A and GABA B receptors have important effects on absence seizures. Systemic administration of the GABA B agonist baclofen aggravates SWDs in models of absence seizures [31] [32] [33] , and induces absence seizures in non-epileptic rats 31, 33 . Conversely, GABA B antagonists have been shown to inhibit SWDs in numerous animal models of absence seizures 31, 32, 34 . GABA A agonists, such as muscimol, administered systemically consistently exacerbate experimental absence seizures 21, 34 . However, GABA A agonists injected centrally have variable effects on absences depending on the site of administration. Microinjections of muscimol into thalamic relay nuclei enhance absence seizures while injections into the NRT inhibit absences 35, 36 . This contrasting effect may be explained by pre-synaptic GABA A receptors acting to suppress the firing of the NRT neurons, and therefore reducing GABA B -mediated IPSP to thalamic relay nuclei. Therefore the pattern of activation of GABA A receptors at different brain sites is critically important in the regulation of thalamocortical oscillatory activity and absence seizures. Further evidence for the importance of GABA receptors in the pathophysiology of absence seizures has come from the recent reports of the first two genetic mutations to be associated with human absence epilepsy, both of which are located within the gene for the γ2-subunit of the GABA A receptor 37, 38 . This subunit is highly expressed in GABA A receptors in the NRT (but not the thalamic relay nuclei) and is critically important in the sensitivity of these receptors to benzodiazepines.
Given the crucial role of GABAergic mechanisms in the regulation of oscillatory thalamocortical activity and absence seizures, one hypothesis for the mechanism of CBZ-induced aggravation of absence seizures is via enhancement of GABAergic function within the thalamic relay nucleus. CBZ has been shown to interact with both GABA A 39 and GABA B 40, 41 receptors. Clinical support for this hypothesis is found in the observation that exacerbations of seizures and/or EEG SWDs by CBZ in epileptic patients is associated with slowing of the background activity on the EEG 42 . Generalised EEG slow wave activity is believed to be mediated by the same thalamocortical network responsible for the generation of rhythmic SWD 43 . It is particularly interesting to note that in our study the frequency of the low-dose PTZ-induced SWD was significantly lower following the administration of CBZ than following vehicle alone ( Table 1) .
The current study was designed to explore the possibility of a gender difference in the susceptibility to the aggravation of absence seizures by CBZ. There is considerable experimental and clinical evidence that post-pubescent females are more susceptible than post-pubescent males to absence epilepsy, and that female sex hormones play a role in modulating absence seizures 7, 11-17, 20, 33, 42, 44, 45 . Previous animal studies have demonstrated that female rats develop more rhythmic SWDs than male rats following low-dose bicuculline administration 33 , and in the AY rat model of atypical absence epilepsy females display three to four times greater SWDs than male rats 10 . This current study did not find any significant gender difference in the total cumulative duration of SWDs during the 90-minute EEG recording following low-dose PTZ administration in the vehicle pre-treatment arm (Table 1) . Furthermore, in contrast to clinical observations, the results of this study did not support the hypothesis that females were significantly more susceptible than males to CBZ-induced aggravation of absence seizures. The main significant gender difference found was that following CBZ pre-treatment, the mean frequency of the SWDs in the low-dose PTZ rat model was lower in female than in male rats ( Table 1) .
The results of this study do not support the hypothesis that post-pubertal females are more susceptible than males to the aggravating effect of CBZ on absence seizures. This hypothesis was based primarily on the clinical observation that most of the reported post-pubescent patients have been pre-menopausal women 7, [11] [12] [13] [14] [15] [16] . This observation may instead reflect a selection bias as a result of absence seizures in adulthood being more common in females than males. An alternative explanation for the results is that the low-dose PTZ model in inbred Sprague-Dawley rats does not display the same gender differences in the susceptibility to CBZ aggravation of absence seizures as human patients. Different rodent models have previously been found to show significant variability in the differences between genders in the expression of SWDs. Male rats of the Brown Norway strain, and their F1 and F2 hybrids, were found to demonstrate greater spontaneous SWDs than their female counterparts, but no gender difference was found for inbred Fischer 344 rats 46 .
Another explanation for the failure of this study to find a significant difference between female and male rats in the CBZ aggravation of PTZ-induced SWD is the confounding effect from the animals' oestrous cycle. Susceptibility to seizures in post-pubescent women with epilepsy commonly varies between different stages of the menstrual cycle, which is believed to relate to variations in relative level of oestrogens and progesterones 47 . Female rats develop more rhythmic SWDs following low-dose bicuculline administration than do male rats, while ovariectomised female rats developed fewer SWDs than intact female rats and this difference disappears following oestradiol supplementation 33 . Additionally, the 3α-hydroxy ring A-reduced metabolites of progesterone, allopregnanolone and pregnanolone, are powerful enhancers of GABA A -mediated responses via interaction with a unique binding site on the receptor complex [48] [49] [50] . Allopregnanolone has been shown to exacerbate SWDs in the genetic WAG/Rij model of absence epilepsy 44 , and ganaxolone, a 3β-methylated synthetic analogue of allopregnanolone, has been demonstrated to exacerbate two pharmacological rat models of absence seizures-the low-dose PTZ model and gamma-butyrolactone (GBL) model 20 . Furthermore, microinjections of two synthetic allopregnanolone analogues, alphaxalone and tetrahydrodeoxycorticosterone, into the ventrobasal thalamic nucleus has been demonstrated to potentiate GBL-induced absence seizures in the rat, while injections into the NRT had no effect 51 . This suggests that the mechanism of absence seizure aggravation by these progesterone metabolites may be via selective activation of GABA A receptors in the thalamic relay nuclei over those in the NRT, likely as a result of molecular heterogeneity of GABA A receptor subunits resulting in differing pharmacological sensitivity. The lower frequency of the SWD seen following CBZ pre-treatment in female rats in our study could potentially reflect a synergistic effect of CBZ with progesterone metabolites on GABA A receptors in thalamic relay nuclei, resulting in a slower frequency of the oscillatory thalamocortical activity. However, we feel that the confounding effect of the oestrous cycle is unlikely to have been a major influence in the lack of gender difference in the aggravation of SWDs by CBZ, because the results of the vaginal smears did not demonstrate any clear relationship with the stage of the oestrous cycle (Table 2 ).
In conclusion, the results of this study demonstrate that CBZ consistently aggravates absence seizures in the low-dose PTZ rat model for both post-pubescent female and male animals. The findings reinforce the importance of avoiding CBZ therapy in patients with primary generalised epilepsies. However, while some gender differences were found, the study failed to confirm that females were significantly more susceptible to CBZ-induced aggravation of experimental absence seizures.
